CD8A and neoplasm: Downregulation or loss of MHC class I reduces tumor immunogenicity, decreases the percentage of CD8 and CD4 tumor infiltrating lymphocytes (TILs) and causes resistance to immunotherapy, which correlates to poor prognosis and patient survival (Garrido et al., 2016).